Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 102.05

+0.3%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rocketman who wrote (574)	3/11/1998 8:52:00 PM
From: George Sepetjian	Read Replies (1) of 3202

Here's some recent INCY analysis. Fiscal fourth-quarter and full-year results show that INCY is gaining earnings momentum. Continued strong sales of the LifeSeq database series fueled an 87% jump in fourth-quarter revenues, to $26.6 million. A 15% drop in operating expenses (as a percentage of revenue) helped boost operating earnings from $0.01 to $0.17 per share. For the year, revenue was up 111%, to $88.4 million, while earnings of $0.43 per share represented a sharp reversal from a ($0.33) loss in fiscal 1996. The strong full year results make us think that the fourth quarter is no flash in the pan. Deepa Pakianathan of Genesis Merchant, is very bullish on INCY's outlook. Genomics companies, especially profitable ones, trade at lofty multiples. INCY traded at more than 100 times earnings throughout much of 1997. Ms. Pakianathan expects the shares to trade up to $62.50 over the next twelve months, based on an assumed P/E multiple of 60 times her fiscal-1998 $0.75 per share earnings estimate.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next